Bausch Health Americas
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bausch Health Americas sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Bausch Health Americas: 168 sponsored US clinical trials, 6 recruiting.
Bausch Health Americas sponsors 168 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 144 completed. 86 of these trials are in Phase 3-4 (later-stage) and 68 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 6 trials.
Top-decile sponsor footprint
Bausch Health Americas ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
144 of 157 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 1 of 4
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
NCT07285785
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
NCT07428538
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
NCT07187297
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
NCT04314375
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03988439
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03987763
A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing
NCT07214272
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
NCT05297448
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
NCT05071716
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
NCT03240809
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
NCT00568997
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
NCT05098028
Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment
NCT05027282
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
NCT04857112
Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
NCT04892706
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
NCT04214652
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
NCT04214639
A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participants With Functional Gastrointestinal Disturbances
NCT04155801
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
NCT03818672
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
NCT03664752
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
NCT03664739
Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
NCT03515044
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects
NCT03058783
Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel
NCT03653403
Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)
NCT03002571
Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03596905
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
NCT03551873
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris
NCT03170388
A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)
NCT03168334
A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)
NCT03168321
Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects
NCT03327558
An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
NCT03120520
Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis
NCT02812771
Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel
NCT02850003
Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
NCT02785185
Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream
NCT02849873
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
NCT02785172
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
NCT02785159
Long Term Safety Study of Plecanatide
NCT02706483
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
NCT02514577
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
NCT02515097
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
NCT02965456
Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
NCT02932306
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
NCT03003247
Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris
NCT02938494
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
NCT02462122
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
NCT02462070
Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
NCT02462083
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
NCT02493452
Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis
NCT02939950
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 37 |
| Phase 3 | 68 |
| Phase 4 | 18 |
What is open in the Bausch Health Americas pipeline
6 recruiting of 168 indexed (4% open); 144 completed (86%).
Phase mix: 86 late (III/IV) vs 68 early (I/II) (balanced across stages).
Top condition: Acne Vulgaris (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bausch Health Americas: open-pipeline peers nationwide
Peers matched on 168 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Bausch Health Americas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
- Sumitomo Pharma America · 168 trials · 4% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Bayer · 4% recruiting · 591 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
Related
What to do with this Bausch Health Americas page
168 registered trials is a research-attention snapshot, not an endorsement of Bausch Health Americas or any single study.
- 6 of Bausch Health Americas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acne Vulgaris is the condition Bausch Health Americas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bausch Health Americas pipeline card: 168 registered trials from official public datasets.Report a data error.